Historical Perspective: Models of Parkinson's Disease
- PMID: 32252301
- PMCID: PMC7177377
- DOI: 10.3390/ijms21072464
Historical Perspective: Models of Parkinson's Disease
Abstract
Parkinson's disease (PD) is the most common movement disorder with motor and nonmotor signs. The current therapeutic regimen for PD is mainly symptomatic as the etio-pathophysiology has not been fully elucidated. A variety of animal models has been generated to study different aspects of the disease for understanding the pathogenesis and therapeutic development. The disease model can be generated through neurotoxin-based or genetic-based approaches in a wide range of animals such as non-human primates (NHP), rodents, zebrafish, Caenorhabditis (C.) elegans, and drosophila. Cellular-based disease model is frequently used because of the ease of manipulation and suitability for large-screen assays. In neurotoxin-induced models, chemicals such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat are used to recapitulate the disease. Genetic manipulation of PD-related genes, such as α-Synuclein(SNCA), Leucine-rich repeat kinase 2 (LRRK2), Pten-Induced Kinase 1 (PINK1), Parkin(PRKN), and Protein deglycase (DJ-1) Are used in the transgenic models. An emerging model that combines both genetic- and neurotoxin-based methods has been generated to study the role of the immune system in the pathogenesis of PD. Here, we discuss the advantages and limitations of the different PD models and their utility for different research purposes.
Keywords: Parkinson disease models; advantages; genetic models; limitations; neurotoxic models.
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
Experimental models of Parkinson's disease: Challenges and Opportunities.Eur J Pharmacol. 2024 Oct 5;980:176819. doi: 10.1016/j.ejphar.2024.176819. Epub 2024 Jul 18. Eur J Pharmacol. 2024. PMID: 39029778 Review.
-
Animal Models for Parkinson's Disease Research: Trends in the 2000s.Int J Mol Sci. 2019 Oct 30;20(21):5402. doi: 10.3390/ijms20215402. Int J Mol Sci. 2019. PMID: 31671557 Free PMC article. Review.
-
Disease model organism for Parkinson disease: Drosophila melanogaster.BMB Rep. 2019 Apr;52(4):250-258. doi: 10.5483/BMBRep.2019.52.4.204. BMB Rep. 2019. PMID: 30545438 Free PMC article. Review.
-
Animal models of Parkinson's disease: a gateway to therapeutics?Neurotherapeutics. 2014 Jan;11(1):92-110. doi: 10.1007/s13311-013-0234-1. Neurotherapeutics. 2014. PMID: 24158912 Free PMC article. Review.
-
Animal Models of Parkinson’s Disease.In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 5. In: Stoker TB, Greenland JC, editors. Parkinson’s Disease: Pathogenesis and Clinical Aspects [Internet]. Brisbane (AU): Codon Publications; 2018 Dec 21. Chapter 5. PMID: 30702844 Free Books & Documents. Review.
Cited by
-
Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinson's Disease.Int J Mol Sci. 2020 Oct 15;21(20):7620. doi: 10.3390/ijms21207620. Int J Mol Sci. 2020. PMID: 33076300 Free PMC article.
-
Multifunctional role of natural products for the treatment of Parkinson's disease: At a glance.Front Pharmacol. 2022 Oct 6;13:976385. doi: 10.3389/fphar.2022.976385. eCollection 2022. Front Pharmacol. 2022. PMID: 36299886 Free PMC article. Review.
-
Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson's Disease.Front Mol Neurosci. 2022 Feb 17;15:805087. doi: 10.3389/fnmol.2022.805087. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35250476 Free PMC article. Review.
-
Rotenone-Induced Model of Parkinson's Disease: Beyond Mitochondrial Complex I Inhibition.Mol Neurobiol. 2023 Apr;60(4):1929-1948. doi: 10.1007/s12035-022-03193-8. Epub 2023 Jan 3. Mol Neurobiol. 2023. PMID: 36593435 Review.
-
The Protection of EGCG Against 6-OHDA-Induced Oxidative Damage by Regulating PPARγ and Nrf2/HO-1 Signaling.Nutr Metab Insights. 2024 May 25;17:11786388241253436. doi: 10.1177/11786388241253436. eCollection 2024. Nutr Metab Insights. 2024. PMID: 38800717 Free PMC article.
References
-
- Stacy M., Bowron A., Guttman M., Hauser R., Hughes K., Larsen J.P., LeWitt P., Oertel W., Quinn N., Sethi K., et al. Identification of motor and nonmotor wearing-off in Parkinson’s disease: Comparison of a patient questionnaire versus a clinician assessment. Mov. Disord. 2005;20:726–733. doi: 10.1002/mds.20383. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous